Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes
John Pullman1, Tamara Darsow2, Juan P Frias21Mercury Street Medical Group, Butte, MT, USA; 2Amylin Pharmaceuticals Inc., 9520 Towne Centre Drive, San Diego, CA, USAAbstract: In patients with diabetes, dysregulation of multiple glucoregulatory hormones results in chronic hyperglycemia and an array of...
Main Authors: | John Pullman, Tamara Darsow, Juan P Frias |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2006-09-01
|
Series: | Vascular Health and Risk Management |
Online Access: | https://www.dovepress.com/pramlintide-in-the-management-of-insulin-using-patients-with-type-2-an-peer-reviewed-article-VHRM |
Similar Items
-
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
by: Tim A Briscoe, Lynette Jobe, et al.
Published: (2008-10-01) -
Reduction in Subcutaneous Insulin Requirements in Tetraplegic Type 1 Diabetic with Cervical Spinal Cord Injury Following Pramlintide Treatment
by: Frank Salamone, BA, et al.
Published: (2020-05-01) -
Meta-Analysis of Exenatide, the Sitagliptin, and Pramlintide Compared to Placebo for Treatment of Type II Diabetes.
by: Rowell, Jonathan, et al.
Published: (2010) -
Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
by: Al-Keilani MS, et al.
Published: (2018-03-01) -
Study of forced degradation behavior of pramlintide acetate by HPLC and LC–MS
by: Yu Yuan, et al.
Published: (2018-01-01)